A Phase 1/2 interventional study of Alpha-1 15% and Liquid Alpha1-Proteinase Inhibitor (Human) in Alpha1-Antitrypsin Deficiency, sponsored by Grifols Therapeutics LLC. Completed at 5 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-08.
Sponsored by Grifols Therapeutics LLC (part of Grifols) · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in alpha 1-Antitrypsin Deficiency by Grifols — 2 open to participants now, 2 under way, 2 of them phase 3. alpha 1-Antitrypsin Deficiency · Grifols.
Among the 12 studies in alpha 1-Antitrypsin Deficiency by Grifols, this one is the 10th largest by enrollment, is the only one that started in 2021, is one of 3 in phase 1/2, and was the 11th registered.
142 studies on the registry are indexed under alpha 1-Antitrypsin Deficiency; 32 are open to participants now.
Browse alpha 1-Antitrypsin Deficiency studies →2 of the 12 studies in alpha 1-Antitrypsin Deficiency by Grifols are open now, in 12 countries. Recruiting first, the newest first:
Grifols Therapeutics LLC · Sites in United States, Denmark, Germany and 6 more countries
Ages 18–80
Grifols Therapeutics LLC · Sites in United States, Australia, Canada and 9 more countries
Ages 20–72
By country, each count listing its studies:
Of the 24 alpha 1-Antitrypsin Deficiency studies recruiting now, 11 (46%) set no upper age limit and 10 (42%) stop at 75 or younger; 4 take children under 18; 5 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 7 · Phase 3 5
First in 2003; this study’s year is marked. 1 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 17 is below the median of 33 across 86 interventional studies indexed under alpha 1-Antitrypsin Deficiency.
Median enrollment 34 across the 12 interventional studies. Of the 10 that completed or were terminated, 9 (90%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Grifols Therapeutics LLC, one of the names counted as Grifols. Under that name alone:
Grifols Therapeutics LLC is the lead sponsor of 46 studies on the registry; 4 are open to participants now.
Of its 13 completed or terminated interventional studies of FDA-regulated products, 13 (100%) have results posted.
1 of the studies in alpha 1-Antitrypsin Deficiency by Grifols that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07555483Phase 3Grifols Therapeutics LLCA Non-inferiority Pharmacokinetic and Safety/Tolerability Study of Two Different Doses of Weekly SC Alpha1-PI 15% Compared With Corresponding Standard IV Alpha1-PI in Participants With Alpha1-Antitrypsin Deficiency (AATD) | 2027-09-30 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies in alpha 1-Antitrypsin Deficiency by Grifols, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety and tolerability of 72 milligrams per kilogram (mg/kg) and 180 mg/kg Alpha-1 15%, administered as a single-dose subcutaneous (SC) infusion and subsequently as weekly SC infusions over 8 weeks in participants with Alpha1-Antitrypsin Deficiency (AATD).
The criteria were revised on the registry on Oct 8, 2026. See what changed
Main Inclusion Criteria:
Main Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive Alpha-1 15% 72 mg/kg, single subcutaneous (SC) infusion in treatment-period 1 (Single-Dose) at Week 1.
Biological: Alpha-1 15%
Following the week-long treatment period 1, participants in Cohort 1 will enter 21 days of washout/serial pharmacokinetic (PK) phase and then the single-dose data evaluation period. During the single-dose data evaluation period, Liquid Alpha1- Proteinase Inhibitor (PI) 60 mg/kg, weekly intravenous (IV) Infusions will be administered from intravenous-dose Week 1 (single-dose Week 5) for up to Week 78, with the last IV dose given 1 week prior to the first repeat Alpha-1 15% SC dose.
Biological: Liquid Alpha1-Proteinase Inhibitor (Human)
Following treatment period 1 and single-dose data evaluation period, participants in Cohort 1 will enter treatment period 2 (Repeat-Dose) and will receive Alpha-1 15% 72 mg/kg, for 8 weekly SC infusions.
Biological: Alpha-1 15%
Participants will receive Alpha-1 15% 180 mg/kg, single SC infusion in treatment-period 1 (Single-Dose) at Week 1.
Biological: Alpha-1 15%
Following the week-long treatment period 1, participants in Cohort 2 will enter 21 days of washout/serial pharmacokinetic (PK) phase and then the single-dose data evaluation period. During the single-dose data evaluation period, Liquid Alpha1-PI 120 mg/kg, weekly IV Infusions will be administered from intravenous-dose Week 1 (single-dose Week 5) for up to Week 78, with the last IV dose given 1 week prior to the first repeat Alpha-1 15% SC dose.
Biological: Liquid Alpha1-Proteinase Inhibitor (Human)
Following treatment period 1 and single-dose data evaluation period, participants in Cohort 2 will enter treatment period 2 (Repeat-Dose) and will receive Alpha-1 15% 180 mg/kg, for 8 weekly SC infusions.
Biological: Alpha-1 15%
Alpha1-Proteinase Inhibitor (Human), 15%, Subcutaneous infusion
Intravenous infusion
Also known as: Prolastin®-C Liquid
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
AE that occurred at any time from the beginning of IP administration until the final visit of the clinical trial was considered TEAE.
Time frame: Up to 668 days
Number of Participants With Suspected Adverse Drug Reactions (ADRs)
All noxious and unintended responses to a medicinal product or study treatment related to any dose was considered suspected ADRs. The phrase "responses to a medicinal product" means that a causal relationship between a medicinal product or study treatment and an AE is at least a reasonable possibility.
Time frame: Up to 668 days
Number of Participants With Infusion Site Reactions (ISRs)
Treatment-emergent ISRs have onset on or after date of the first administration of study treatment up to on or before 28 days after last administration of study treatment. An ISR was counted in the period during which it started.
Time frame: Up to 668 days
Number of Participants With Serious Adverse Events (SAEs)
An adverse event is considered serious if, in the judgment of the investigator or sponsor, it results in death, is life-threatening, requires hospitalization or prolongs an existing hospitalization (admission for 24 hours or more, including emergency room stays), causes significant or persistent disability, results in a congenital anomaly or birth defect, or is an important medical event that may jeopardize the subject or require intervention to prevent these outcomes.
Time frame: Up to 668 days
Number of Participants With Any TEAE Leading to Study Withdrawal
TEAE Leading to Study Withdrawal refers to a TEAE that results in a participant permanently discontinuing or withdrawing from a clinical study because of the adverse event.
Time frame: Up to 668 days
Number of Participants With Chronic Obstructive Pulmonary Disease (COPD) Exacerbations
The definition of an exacerbation of COPD is an increase in respiratory symptoms (dyspnea, increased cough, and/or production of sputum) over baseline that usually requires medical intervention.
Time frame: Up to 668 days
Number of Participants With Any Adverse Events Associated With Abnormalities in Vital Signs (Heart Rate, Blood Pressure, Respiratory Rate, and Temperature)
Clinically significant vital sign abnormalities were presented as adverse events, with clinical relevance based on the Investigator's judgment.
Time frame: Up to 668 days
Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1)
FEV1 was performed according to ATS/ERS guidelines. At each visit, testing was performed both pre- and post-bronchodilator (BD) administration.
Time frame: Single-Dose Week 5/Intravenous Week 1, and Repeat-Dose Weeks 1, 4, and 9
Change From Baseline in Forced Vital Capacity (FVC)
FVC was performed according to ATS/ERS guidelines. At each visit, testing was performed both pre- and post-bronchodilator (BD) administration.
Time frame: Single-Dose Week 5/Intravenous Week 1, and Repeat-Dose Weeks 1, 4, and 9
Number of Participants With Any Adverse Events Associated With Abnormalities in Laboratory Parameters (Chemistry, Hematology, Urinalysis)
Out of the normal range laboratory results judged by the Investigator as clinically significant in the context of the participant's medical history were considered adverse events.
Time frame: Up to 668 days
Immunogenicity: Number of Participants With Alpha1-PI Antibodies
Immunogenicity testing was performed using validated assays in a multi-tiered approach.
Time frame: Treatment Period 1- Single-Dose Week 1; Treatment Period 2- Repeat-Dose Weeks 1 and 9
| Milestone | Cohort 1 | Cohort 2 |
|---|---|---|
| Started | 9 | 8 |
| Completed | 5 | 6 |
| Not completed | 4 | 2 |
AE that occurred at any time from the beginning of IP administration until the final visit of the clinical trial was considered TEAE.
| Participants | Cohort 1: Treatment Period 1 (Alpha-1 15%, 72 mg/kg) | Cohort 1: Single-Dose Data Evaluation Period (Liquid Alpha 1-Proteinase Inhibitor 60 mg/kg) | Cohort 1: Treatment Period 2 (Alpha-1 15%, 72 mg/kg) | Cohort 2: Treatment Period 1 (Alpha-1 15%, 180 mg/kg) | Cohort 2: Single-Dose Data Evaluation Period (Liquid Alpha1-Proteinase Inhibitor 120 mg/kg) | Cohort 2: Treatment Period 2 (Alpha-1 15%, 180 mg/kg) |
|---|---|---|---|---|---|---|
| Number of Participants With Treatment Emergent Adverse Events (TEAEs) | 5 | 7 | 3 | 3 | 7 | 4 |
All noxious and unintended responses to a medicinal product or study treatment related to any dose was considered suspected ADRs. The phrase "responses to a medicinal product" means that a causal relationship between a medicinal product or study treatment and an AE is at least a reasonable possibility.
| Participants | Cohort 1: Treatment Period 1 (Alpha-1 15%, 72 mg/kg) | Cohort 1: Single-Dose Data Evaluation Period (Liquid Alpha 1-Proteinase Inhibitor 60 mg/kg) | Cohort 1: Treatment Period 2 (Alpha-1 15%, 72 mg/kg) | Cohort 2: Treatment Period 1 (Alpha-1 15%, 180 mg/kg) | Cohort 2: Single-Dose Data Evaluation Period (Liquid Alpha1-Proteinase Inhibitor 120 mg/kg) | Cohort 2: Treatment Period 2 (Alpha-1 15%, 180 mg/kg) |
|---|---|---|---|---|---|---|
| Number of Participants With Suspected Adverse Drug Reactions (ADRs) | 3 | 2 | 1 | 2 | 2 | 3 |
Treatment-emergent ISRs have onset on or after date of the first administration of study treatment up to on or before 28 days after last administration of study treatment. An ISR was counted in the period during which it started.
| Participants | Cohort 1: Treatment Period 1 (Alpha-1 15%, 72 mg/kg) | Cohort 1: Single-Dose Data Evaluation Period (Liquid Alpha 1-Proteinase Inhibitor 60 mg/kg) | Cohort 1: Treatment Period 2 (Alpha-1 15%, 72 mg/kg) | Cohort 2: Treatment Period 1 (Alpha-1 15%, 180 mg/kg) | Cohort 2: Single-Dose Data Evaluation Period (Liquid Alpha1-Proteinase Inhibitor 120 mg/kg) | Cohort 2: Treatment Period 2 (Alpha-1 15%, 180 mg/kg) |
|---|---|---|---|---|---|---|
| Number of Participants With Infusion Site Reactions (ISRs) | 3 | 0 | 1 | 2 | 0 | 2 |
An adverse event is considered serious if, in the judgment of the investigator or sponsor, it results in death, is life-threatening, requires hospitalization or prolongs an existing hospitalization (admission for 24 hours or more, including emergency room stays), causes significant or persistent disability, results in a congenital anomaly or birth defect, or is an important medical event that may jeopardize the subject or require intervention to prevent these outcomes.
| Participants | Cohort 1: Treatment Period 1 (Alpha-1 15%, 72 mg/kg) | Cohort 1: Single-Dose Data Evaluation Period (Liquid Alpha 1-Proteinase Inhibitor 60 mg/kg) | Cohort 1: Treatment Period 2 (Alpha-1 15%, 72 mg/kg) | Cohort 2: Treatment Period 1 (Alpha-1 15%, 180 mg/kg) | Cohort 2: Single-Dose Data Evaluation Period (Liquid Alpha1-Proteinase Inhibitor 120 mg/kg) | Cohort 2: Treatment Period 2 (Alpha-1 15%, 180 mg/kg) |
|---|---|---|---|---|---|---|
| Number of Participants With Serious Adverse Events (SAEs) | 0 | 0 | 1 | 0 | 2 | 1 |
TEAE Leading to Study Withdrawal refers to a TEAE that results in a participant permanently discontinuing or withdrawing from a clinical study because of the adverse event.
| Participants | Cohort 1: Treatment Period 1 (Alpha-1 15%, 72 mg/kg) | Cohort 1: Single-Dose Data Evaluation Period (Liquid Alpha 1-Proteinase Inhibitor 60 mg/kg) | Cohort 1: Treatment Period 2 (Alpha-1 15%, 72 mg/kg) | Cohort 2: Treatment Period 1 (Alpha-1 15%, 180 mg/kg) | Cohort 2: Single-Dose Data Evaluation Period (Liquid Alpha1-Proteinase Inhibitor 120 mg/kg) | Cohort 2: Treatment Period 2 (Alpha-1 15%, 180 mg/kg) |
|---|---|---|---|---|---|---|
| Number of Participants With Any TEAE Leading to Study Withdrawal | 1 | 1 | 1 | 0 | 0 | 1 |
The definition of an exacerbation of COPD is an increase in respiratory symptoms (dyspnea, increased cough, and/or production of sputum) over baseline that usually requires medical intervention.
| Participants | Cohort 1: Treatment Period 1 (Alpha-1 15%, 72 mg/kg) | Cohort 1: Single-Dose Data Evaluation Period (Liquid Alpha 1-Proteinase Inhibitor 60 mg/kg) | Cohort 1: Treatment Period 2 (Alpha-1 15%, 72 mg/kg) | Cohort 2: Treatment Period 1 (Alpha-1 15%, 180 mg/kg) | Cohort 2: Single-Dose Data Evaluation Period (Liquid Alpha1-Proteinase Inhibitor 120 mg/kg) | Cohort 2: Treatment Period 2 (Alpha-1 15%, 180 mg/kg) |
|---|---|---|---|---|---|---|
| Number of Participants With Chronic Obstructive Pulmonary Disease (COPD) Exacerbations | 1 | 2 | 2 | 0 | 2 | 1 |
Clinically significant vital sign abnormalities were presented as adverse events, with clinical relevance based on the Investigator's judgment.
| Participants | Cohort 1: Treatment Period 1 (Alpha-1 15%, 72 mg/kg) | Cohort 1: Single-Dose Data Evaluation Period (Liquid Alpha 1-Proteinase Inhibitor 60 mg/kg) | Cohort 1: Treatment Period 2 (Alpha-1 15%, 72 mg/kg) | Cohort 2: Treatment Period 1 (Alpha-1 15%, 180 mg/kg) | Cohort 2: Single-Dose Data Evaluation Period (Liquid Alpha1-Proteinase Inhibitor 120 mg/kg) | Cohort 2: Treatment Period 2 (Alpha-1 15%, 180 mg/kg) |
|---|---|---|---|---|---|---|
| Number of Participants With Any Adverse Events Associated With Abnormalities in Vital Signs (Heart Rate, Blood Pressure, Respiratory Rate, and Temperature) | 0 | 1 | 0 | 0 | 1 | 0 |
FEV1 was performed according to ATS/ERS guidelines. At each visit, testing was performed both pre- and post-bronchodilator (BD) administration.
| litres | Cohort 1 | Cohort 2 |
|---|---|---|
| Pre-BD - IV Week 1 | -0.093 ± 0.1381 | -0.016 ± 0.1098 |
| Pre-BD - RD Week 1 | -0.033 ± 0.1532 | -0.029 ± 0.1160 |
| Pre-BD - RD Week 4 | 0.110 ± 0.3107 | 0.006 ± 0.1477 |
| Pre-BD - RD Week 9 | 0.080 ± 0.1138 | 0.013 ± 0.1473 |
| Post-BD - IV Week 1 | -0.031 ± 0.1391 | 0.004 ± 0.0737 |
| Post-BD - RD Week 1 | -0.058 ± 0.0917 | -0.034 ± 0.0998 |
| Post-BD - RD Week 4 | 0.104 ± 0.1937 | 0.016 ± 0.1332 |
| Post-BD - RD Week 9 | 0.158 ± 0.3088 | 0.053 ± 0.0900 |
FVC was performed according to ATS/ERS guidelines. At each visit, testing was performed both pre- and post-bronchodilator (BD) administration.
| litres | Cohort 1 | Cohort 2 |
|---|---|---|
| Pre-BD - IV Week 1 | -0.149 ± 0.2432 | -0.156 ± 0.2787 |
| Pre-BD - RD Week 1 | -0.025 ± 0.2716 | 0.310 ± 0.3024 |
| Pre-BD - RD Week 4 | 0.128 ± 0.4371 | -0.296 ± 0.2666 |
| Pre-BD - RD Week 9 | 0.114 ± 0.2086 | -0.185 ± 0.3247 |
| Post-BD - IV Week 1 | -0.059 ± 0.1377 | -0.120 ± 0.2017 |
| Post-BD - RD Week 1 | -0.003 ± 0.2085 | -0.327 ± 0.3813 |
| Post-BD - RD Week 4 | 0.172 ± 0.3729 | -0.322 ± 0.4258 |
| Post-BD - RD Week 9 | 0.114 ± 0.2185 | -0.143 ± 0.3649 |
Out of the normal range laboratory results judged by the Investigator as clinically significant in the context of the participant's medical history were considered adverse events.
| Participants | Cohort 1: Treatment Period 1 (Alpha-1 15%, 72 mg/kg) | Cohort 1: Single-Dose Data Evaluation Period (Liquid Alpha 1-Proteinase Inhibitor 60 mg/kg) | Cohort 1: Treatment Period 2 (Alpha-1 15%, 72 mg/kg) | Cohort 2: Treatment Period 1 (Alpha-1 15%, 180 mg/kg) | Cohort 2: Single-Dose Data Evaluation Period (Liquid Alpha1-Proteinase Inhibitor 120 mg/kg) | Cohort 2: Treatment Period 2 (Alpha-1 15%, 180 mg/kg) |
|---|---|---|---|---|---|---|
| Number of Participants With Any Adverse Events Associated With Abnormalities in Laboratory Parameters (Chemistry, Hematology, Urinalysis) | 0 | 0 | 0 | 0 | 1 | 1 |
Immunogenicity testing was performed using validated assays in a multi-tiered approach.
| Participants | Cohort 1 | Cohort 2 |
|---|---|---|
| Immunogenicity: Number of Participants With Alpha1-PI Antibodies | 0 | 0 |
Collected over Up to 668 days. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1: Treatment Period 1 (Alpha-1 15%, 72 mg/kg) | 0/9 (0%) | 0/9 (0%) | 5/9 (55.6%) |
| Cohort 1: Single-Dose Data Evaluation Period (Liquid Alpha 1-Proteinase Inhibitor 60 mg/kg) | 0/8 (0%) | 0/8 (0%) | 7/8 (87.5%) |
| Cohort 1: Treatment Period 2 (Alpha-1 15%, 72 mg/kg) | 0/6 (0%) | 1/6 (16.7%) | 3/6 (50%) |
| Cohort 2: Treatment Period 1 (Alpha-1 15%, 180 mg/kg) | 0/8 (0%) | 0/8 (0%) | 3/8 (37.5%) |
| Cohort 2: Single-Dose Data Evaluation Period (Liquid Alpha1-Proteinase Inhibitor 120 mg/kg) | 0/8 (0%) | 2/8 (25%) | 7/8 (87.5%) |
| Cohort 2: Treatment Period 2 (Alpha-1 15%, 180 mg/kg) | 0/7 (0%) | 1/7 (14.3%) | 4/7 (57.1%) |
| Event | Cohort 1: Treatment Period 1 (Alpha-1 15%, 72 mg/kg) | Cohort 1: Single-Dose Data Evaluation Period (Liquid Alpha 1-Proteinase Inhibitor 60 mg/kg) | Cohort 1: Treatment Period 2 (Alpha-1 15%, 72 mg/kg) | Cohort 2: Treatment Period 1 (Alpha-1 15%, 180 mg/kg) | Cohort 2: Single-Dose Data Evaluation Period (Liquid Alpha1-Proteinase Inhibitor 120 mg/kg) | Cohort 2: Treatment Period 2 (Alpha-1 15%, 180 mg/kg) |
|---|---|---|---|---|---|---|
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 0/9 | 0/8 | 1/6 | 0/8 | 1/8 | 0/7 |
| Acute promyelocytic leukaemiaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/9 | 0/8 | 0/6 | 0/8 | 0/8 | 1/7 |
| Chronic respiratory failureRespiratory, thoracic and mediastinal disorders | 0/9 | 0/8 | 0/6 | 0/8 | 1/8 | 0/7 |
| Hip fractureInjury, poisoning and procedural complications | 0/9 | 0/8 | 0/6 | 0/8 | 1/8 | 0/7 |
| Event | Cohort 1: Treatment Period 1 (Alpha-1 15%, 72 mg/kg) | Cohort 1: Single-Dose Data Evaluation Period (Liquid Alpha 1-Proteinase Inhibitor 60 mg/kg) | Cohort 1: Treatment Period 2 (Alpha-1 15%, 72 mg/kg) | Cohort 2: Treatment Period 1 (Alpha-1 15%, 180 mg/kg) | Cohort 2: Single-Dose Data Evaluation Period (Liquid Alpha1-Proteinase Inhibitor 120 mg/kg) | Cohort 2: Treatment Period 2 (Alpha-1 15%, 180 mg/kg) |
|---|---|---|---|---|---|---|
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 1/9 | 2/8 | 1/6 | 0/8 | 2/8 | 1/7 |
| WheezingRespiratory, thoracic and mediastinal disorders | 0/9 | 2/8 | 0/6 | 0/8 | 0/8 | 0/7 |
| COVID-19Infections and infestations | 0/9 | 2/8 | 0/6 | 0/8 | 0/8 | 0/7 |
| Infusion site painGeneral disorders | 0/9 | 0/8 | 0/6 | 2/8 | 0/8 | 0/7 |
| Infusion site erythemaGeneral disorders | 2/9 | 0/8 | 0/6 | 0/8 | 0/8 | 0/7 |
| Infusion site reactionGeneral disorders | 0/9 | 0/8 | 1/6 | 0/8 | 0/8 | 0/7 |
| Vaginal infectionInfections and infestations | 0/9 | 0/8 | 1/6 | 0/8 | 0/8 | 0/7 |
| NauseaGastrointestinal disorders | 0/9 | 1/8 | 0/6 | 0/8 | 1/8 | 1/7 |
| Infusion site bruisingGeneral disorders | 0/9 | 0/8 | 0/6 | 0/8 | 0/8 | 1/7 |
| Infusion site dermatitisGeneral disorders | 0/9 | 0/8 | 0/6 | 0/8 | 0/8 | 1/7 |
The Safety Population included all participants who received any dose of study treatment (Alpha-1 15% or Liquid Alpha1-PI) and were used for all analyses and summaries other than those for PK.
| Age, Continuous(years) | Cohort 1 | Cohort 2 | Total |
|---|---|---|---|
| Mean | 63.8 ± 5.74 | 69.1 ± 7.59 | 66.3 ± 7.02 |
| Sex: Female, Male(Participants) | Cohort 1 | Cohort 2 | Total |
|---|---|---|---|
| Female | 5 | 6 | 11 |
| Male | 4 | 2 | 6 |
| Race (NIH/OMB)(Participants) | Cohort 1 | Cohort 2 | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 9 | 8 | 17 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | Cohort 1 | Cohort 2 | Total |
|---|---|---|---|
| Hispanic or Latino | 2 | 0 | 2 |
| Not Hispanic or Latino | 7 | 8 | 15 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Cohort 1 | Cohort 2 | Total |
|---|---|---|---|
| United States | 9 | 8 | 17 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Dec 2021 to primary completion in Aug 2025, 43 months.
Results were first posted in Oct 2026, 1 year 2 months after primary completion.
Start moved once since we started tracking on Sep 25, 2026: Aug 2021 → Dec 2021, on Oct 8, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Homo sapiens whole
alpha 1-Antitrypsin Deficiency →